Literature DB >> 28817320

Tobacco Industry Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away Our Business It Should Be Us".

Dorie Apollonio1, Stanton A Glantz1.   

Abstract

Nicotine replacement therapy (NRT) is recommended for tobacco cessation on the basis of pharmaceutical industry research showing its effectiveness when combined with counseling. The tobacco industry opposed NRT when it first appeared in the 1980s but by 2016 was marketing its own NRT products. We used internal tobacco industry documents dated 1960 through 2010 to identify the industry's perceptions of NRT. As early as the 1950s, tobacco companies developed nonsmoked nicotine replacements for cigarettes, but they stopped out of concern that marketing such products would trigger Food and Drug Administration regulation of cigarettes. In the 1990s, after pharmaceutical companies began selling prescription NRT, tobacco companies found that many smokers used NRT to supplement smoking rather than to quit. In 2009, once the Food and Drug Administration began regulating tobacco, tobacco companies restarted their plans to capture the nicotine market. Although the tobacco industry initially viewed NRT as a threat, it found that smokers often combined NRT with smoking rather than using it as a replacement and began marketing their own NRT products.

Entities:  

Mesh:

Year:  2017        PMID: 28817320      PMCID: PMC5599147          DOI: 10.2105/AJPH.2017.303935

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  35 in total

Review 1.  Implications of the tobacco industry documents for public health and policy.

Authors:  Lisa Bero
Journal:  Annu Rev Public Health       Date:  2001-11-06       Impact factor: 21.981

2.  Physicians' counseling of patients when prescribing nicotine replacement therapy.

Authors:  Saul Shiffman; Stuart G Ferguson; Stephen J Hellebusch
Journal:  Addict Behav       Date:  2006-07-26       Impact factor: 3.913

3.  Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study.

Authors:  Patrick Marcellin; Michel Chousterman; Thierry Fontanges; Denis Ouzan; Michel Rotily; Marina Varastet; Jean-Philippe Lang; Pascal Melin; Patrice Cacoub
Journal:  Liver Int       Date:  2011-02-15       Impact factor: 5.828

4.  Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation.

Authors:  M Davidson; M Epstein; R Burt; C Schaefer; G Whitworth; A McDonald
Journal:  Arch Fam Med       Date:  1998 Nov-Dec

5.  Looking through a keyhole at the tobacco industry. The Brown and Williamson documents.

Authors:  S A Glantz; D E Barnes; L Bero; P Hanauer; J Slade
Journal:  JAMA       Date:  1995-07-19       Impact factor: 56.272

6.  Efficacy of over-the-counter nicotine patch.

Authors:  Saul Shiffman; Jane Gorsline; Charles W Gorodetzky
Journal:  Nicotine Tob Res       Date:  2002-11       Impact factor: 4.244

7.  Designing "Real-World" trials to meet the needs of health policy makers at marketing authorization.

Authors:  Melanie Calvert; John Wood; Nick Freemantle
Journal:  J Clin Epidemiol       Date:  2011-03-31       Impact factor: 6.437

8.  Analysis of British American Tobacco's questionable use of privilege and protected document claims at the Guildford Depository.

Authors:  Eric LeGresley; Kelley Lee
Journal:  Tob Control       Date:  2016-06-27       Impact factor: 7.552

Review 9.  Adherence in ulcerative colitis: an overview.

Authors:  Anna Testa; Fabiana Castiglione; Olga Maria Nardone; Giorgio L Colombo
Journal:  Patient Prefer Adherence       Date:  2017-02-22       Impact factor: 2.711

10.  Who has used internal company documents for biomedical and public health research and where did they find them?

Authors:  L Susan Wieland; Lainie Rutkow; S Swaroop Vedula; Christopher N Kaufmann; Lori M Rosman; Claire Twose; Nirosha Mahendraratnam; Kay Dickersin
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

View more
  14 in total

1.  Tobacco company strategies to identify and promote the benefits of nicotine.

Authors:  Pamela M Ling; Stanton A Glantz
Journal:  Tob Control       Date:  2018-08-09       Impact factor: 7.552

2.  Health Care Provider Intervention and Utilization of Cessation Assistance in 12 Low- and Middle-Income Countries.

Authors:  Daniel Owusu; Ke-Sheng Wang; Megan Quinn; Jocelyn Aibangbee; Rijo M John; Hadii M Mamudu
Journal:  Nicotine Tob Res       Date:  2019-01-04       Impact factor: 4.244

3.  Placement and sales of tobacco products and nicotine replacement therapy in tobacco-free and tobacco-selling pharmacies in Northern California: an observational study.

Authors:  Liriany Pimentel; Dorie E Apollonio
Journal:  BMJ Open       Date:  2019-06-14       Impact factor: 2.692

4.  Lucy-Novel Flavored Nicotine Gum, Lozenges, and Pouches: Are They Misleading Consumers?

Authors:  Jennifer B Unger; Joshua Barker; Tess Boley Cruz; Adam M Leventhal; Mary Ann Pentz
Journal:  Subst Use Misuse       Date:  2022-05-19       Impact factor: 2.362

5.  PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.

Authors:  Stanton A Glantz
Journal:  Tob Control       Date:  2018-08-21       Impact factor: 7.552

6.  E-Cigarettes: Use, Effects on Smoking, Risks, and Policy Implications.

Authors:  Stanton A Glantz; David W Bareham
Journal:  Annu Rev Public Health       Date:  2018-01-11       Impact factor: 21.981

7.  Successful countering of tobacco industry efforts to overturn Thailand's ENDS ban.

Authors:  Roengrudee Patanavanich; Stanton Glantz
Journal:  Tob Control       Date:  2020-11-23       Impact factor: 7.552

8.  Public versus internal conceptions of addiction: An analysis of internal Philip Morris documents.

Authors:  Jesse Elias; Yogi Hale Hendlin; Pamela M Ling
Journal:  PLoS Med       Date:  2018-05-01       Impact factor: 11.069

9.  Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control.

Authors:  Stella A Bialous; Stanton A Glantz
Journal:  Tob Control       Date:  2018-09-12       Impact factor: 7.552

10.  Comparison of volatile organic compounds between cigarette smoke condensate (CSC) and extract (CSE) samples.

Authors:  Yong-Hyun Kim; Young-Ji An; Seongwon Jo; Sang-Hyub Lee; Sang Jin Lee; Seong-Jin Choi; Kyuhong Lee
Journal:  Environ Health Toxicol       Date:  2018-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.